Pliant Therapeutics

Innovating Integrin-Based Therapies

South San Francisco, CA, United States

Pliant Therapeutics is a company developing treatments for fibrotic diseases.

Shareable draft

Check out Pliant Therapeutics on @MedStartr Today Pliant Therapeutics is a company developing treatments for fibrotic diseases. #IdiopathicPulmonaryFibrosisIPF #PrimarySclerosingCholangitisPSC #NonalcoholicSteatohepatitisNASHWithLiverFibrosis #MuscularDystrophies #MentalBehavioralHealth #SolidTumors #FibroticDiseases #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/rM18UIPDddA

Get Involved in Pliant Therapeutics

How We Help

Problem Statement

Pliant Therapeutics aims to address the unmet medical needs in fibrotic diseases, solid tumors, and muscular dystrophies by developing novel integrin-based therapies that are potentially safer and more effective than existing treatments.

Core Technology

Proprietary integrin discovery platform

Key Differentiators

Leadership in the development of integrin-based therapeutics, proprietary drug discovery platform, focus on understanding and applying the role of integrins in diseases to unlock potentially safer and more effective therapies, and a precision medicine approach.

Clinical Focus

Fibrotic diseases, solid tumors, muscular dystrophies

Product Stage

Beta

Company Info

Business Model: Clinical-stage Biopharmaceutical
Founded: 2015
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: pliantrx.com

Disease Areas

Idiopathic Pulmonary Fibrosis (IPF)Primary Sclerosing Cholangitis (PSC)Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis Muscular Dystrophies Mental Health Solid Tumors Fibrotic Diseases

Technologies

Precision Medicine TechIntegrin-Based TherapeuticsIntegrin Discovery Platform

Clinical & IP

🔬

Clinical Validation

Bexotegrast: FDA Fast Track + Orphan Drug designation (PSC, IPF). INTEGRIS-PSC Phase 2a positive (320mg well-tolerated, improved liver stiffness p<0.05, improved ALP p<0.05 at 24 weeks, followed through 40 weeks). PLN-101095: Phase 1a/1b interim data shows 40% response rate (4/10 ICI-refractory: 1 CR, 3 PR) in secondary-refractory patients with median 15-month durability. Multiple tumor types responding: cholangiocarcinoma, melanoma, HNSCC, NSCLC.

🌐Website

MedStartr Engagement Score

Too Big!

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Pliant Therapeutics?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.